FutureTech II Acquisition Corp. announced that on August 12, 2025, it entered into a merger agreement with Longevity Biomedical, involving the acquisition of Cerevast Medical and Aegeria Soft Tissue, which will ultimately result in Longevity as a subsidiary of a newly formed public company listed on Nasdaq under the symbol 'LBIO'. This filing is significant for investors as it outlines a major restructuring and merger process.